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At the outset, it is worth noting that,
for historical reasons, I have referred to
D6/ACKR2 as “D6” throughout the major-
ity of this essay. Issues relating to the com-
plexity of D6 nomenclature are discussed
below.
IN THE BEGINNING . . .
Very much in keeping with the name of
the chemokine receptor subfamily to which
D6 belongs, the majority of my research
in the field of chemokine biology has
been “atypical” in the sense that it has
rarely focused on classical immunological
roles for these molecules. Indeed, the story
behind the discovery of D6 starts from an
unusual research perspective! In 1988, I was
employed as a postdoctoral researcher in
the laboratory of Prof. Ian Pragnell who
became a close friend, and with whom
I enjoyed many international adventures.
Ian, at the time, was interested in trying to
identify inhibitors of hematopoietic stem
cell proliferation with the idea that these
might be used as myelo protective agents
during cancer chemotherapy. He had iden-
tified an“activity”in the conditioned media
of J774 cells, which was capable of induc-
ing quiescence in primary murine and
human hematopoietic stem cells and my
job was to purify and characterizes this fac-
tor. The protein responsible for this activ-
ity proved reasonably easy to purify and
turned out to be CCL3 although, at the
time, we called it stem cell inhibitor, or SCI.
This work was published in Nature in 1990
(1) and represented the first demonstra-
tion of a role for chemokines in regulat-
ing stem cell function and this, of course,
has now become a prominent sub spe-
cialty in the chemokine field. The next
objective was to clone the receptor for this
stem cell inhibitor. I spent a frustrating
period of time trying to “expression clone”
this CCL3 receptor from “stem cell like”
cell lines but these approaches met with
little success. Alternative approaches were
needed.
THE CLONING OF D6
In 1993, I was lucky to be able to recruit,
to the group, a very talented young post
doctoral researcher named Rob Nibbs who
was (and is!) a highly gifted molecular biol-
ogist. Rob then set about developing new
strategies for the cloning of CCL3 recep-
tors. At this stage, only CCR1 had been
identified and we had shown that this was
not involved in mediating the stem cell
inhibitory effects of CCL3 suggesting that
an, as yet unidentified receptor, was key.
Rob set his mind on using a degenerate
genomic PCR cloning strategy based on
the emerging indications that the major-
ity of the coding regions for chemokine
receptors were incorporated within a sin-
gle genomic exon. This strategy led to the
identification of a number of novel murine
chemokine receptors. Frustratingly, as is
the way in competitive science, a num-
ber of these receptors were published by
other groups just as we were drafting out
our publications reporting their cloning.
However, one receptor that we had iden-
tified was not published by other groups
and was reported by us under the name
of “D6” in 1997 (2). Notably, Steiner and
colleagues also reported the cloning of D6
around the same time (3) but they did
not pursue further biological studies of
this molecule. Shortly after the cloning of
murine D6, we reported the cloning of the
human homolog (4). One of the curious
features of both murine and human D6 was
that they lacked the canonical DRYLAIV
motif, which had been found in all other
cloned chemokine receptors and which was
regarded as being important for cellular
signaling. This suggested an unusual aspect
to the biology of D6 function.
THE EXPRESSION OF D6
In collaboration with Paul Ponath, and his
colleagues at Leukosite (a former Biotech
company in the United States), we gener-
ated monoclonal antibodies to human D6
and used these to demonstrate that the
predominant cells expressing D6 in adult
tissues were lymphatic endothelial cells
(5). In addition, strong D6 expression was
seen throughout the syncytiotrophoblast
layer in the placenta and expression was
also noted on some leukocyte subtype (6).
Therefore, again in keeping with the atyp-
ical nature of this molecule, D6 expression
patterns were markedly different from the
other chemokine receptors further suggest-
ing unusual aspects to D6 biology.
INSIGHTS INTO D6 FUNCTION
Exhaustive ligand binding studies demon-
strated that D6 was a highly promis-
cuous receptor capable of binding the
majority of (if not all) inflammatory CC-
chemokines. It did not bind homeosta-
tic CC-chemokines not did it bind CXC,
XC, or CX3C chemokines. We there-
fore characterized it as a promiscuous
receptor with a specificity for inflam-
matory CC-chemokines. Binding affini-
ties for the ligands were generally in the
high pM and low nM range and there-
fore equivalent to those seen with the
other chemokine receptors. In keeping
with the altered DRYLAIV motif, and
contrary to data reported in our initial
cloning paper (2) (which we presume
was a consequence of a mutation intro-
duced into the receptor clone used), we
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were never able to demonstrate signaling
through D6 or chemotactic responses in
cells expressing this receptor. This led
us to the tentative assumption that D6
was a non-signaling chemokine receptor
[more recent observations from our Milan
colleagues have suggested “atypical” sig-
naling pathways downstream of ligand
binding by D6 (7)] but quite what this
meant for function was not immediately
apparent.
The breakthrough was provided when
Alberto Mantovani and Massimo Locati
and their group in Milan demonstrated
that D6 was capable of internalizing
and effectively scavenging its ligands (8).
Shortly after, we showed that D6 sponta-
neously internalized and recycled to the
cell membrane in any cell type, which it
was expressed (9). Together, these observa-
tions led to a model of D6 function, which
proposed that D6 does not support cellu-
lar migration but that, following binding, it
internalizes ligand and deposits it in lyso-
somes for intracellular degradation. The
great advantage of D6 is its promiscuity
and all the analyses that we, and our Milan
colleagues, have performed have demon-
strated that it is an exquisitely efficient scav-
enger of inflammatory CC-chemokines.
Notably, all these data were generated using
in vitro approaches and so the next chal-
lenge was to demonstrate a role for D6
in vivo and to see if such a role was com-
patible with in vivo chemokine scavenging
activity.
D6 IN VIVO
Our next target was to generate D6-
deficient mice to allow us to study their
responses in a range of inflammatory mod-
els. At the time, this was not an area of
expertise that we possessed and so I ini-
tiated a collaboration with our friends Don
Cook and Sergio Lira who were expert in
this area and who were both, at the time,
employed by the Schering-Plough Research
Institute in Kenilworth New Jersey. Don
quickly generated the D6-deficient mice
and sent them to us for analysis. Import of
these mice into Scotland, however, did not
go quite as smoothly as initially planned!
During the flight from the United States
to Scotland, the mice managed to gnaw
through the wall of the container in which
they had been kept. Once the authorities
discovered this they were concerned that
mice might have escaped into the electrics
of the aeroplane and might therefore cause
serious problems with the plane’s func-
tion. We therefore had to prove, without
doubt, that no mice had escaped from the
cage. Fortunately, the mice were not suf-
ficiently interested in exploring the plane
and we were able to demonstrate that
all mice that had been sent remained in
the cage. This was a massive relief as the
cost of stripping down, and rebuilding,
a Jumbo Jet to find a lost mouse would
have bankrupted the Institute in which
Rob and I were employed at the time!
Anyway, the mice arrived safely and we
proceeded to examine their responses in
a relatively simple model of cutaneous
inflammation involving the topical appli-
cation of the phorbol ester TPA. What we
found, and very much in keeping with a
role for D6 as a scavenger of inflammatory
chemokines, was that these mice displayed
an inability to effectively resolve this cuta-
neous inflammatory response. Indeed, the
mice developed a pathology that displayed
remarkable similarities to human psoria-
sis. This work was published in Nature
Immunology in 2005 (10) and was followed
by numerous other studies in different tis-
sue systems both from our own group and
from the Milan group (11). Together these
studies unequivocally demonstrated a role
for D6 in the resolution of inflammatory
response. The importance of D6 for scav-
enging inflammatory CC-chemokines was
also reflected in other pathological pheno-
types in D6-deficient mice. For example,
and as mentioned above, a major site of D6
expression is the syncytiotrophoblast layer
of the placenta and D6-deficient mice dis-
play enhanced susceptibility to miscarriage
in response to maternal systemic inflam-
mation (12). In addition,D6-deficient mice
display exaggerated tumorigenic programs
in a variety of inflammation-dependent
cancer models. D6 is therefore a scavenger
of inflammatory chemokines with impor-
tant roles to play in a range of tissue and
pathological, contexts. Notably, we have
recently published evidence indicating a
developmental role for D6 in regulating
the density of lymphatic vessel networks
in embryonic skin (13). Together these
studies implicate the D6 in the regula-
tion of pro-lymphangionenic macrophage
proximity to developing lymphatic vessel
networks and provide the first evidence
of a role for inflammatory chemokines,
and their regulators, in developmental
processes.
THE NOMENCLATURE PROBLEM!
The name “D6” refers to nothing more
complicated than the coordinates, on a
multiwell plate, of the clone encoding this
receptor. As mentioned above, we erro-
neously initially believed that D6 was a clas-
sical signaling molecule and therefore con-
tacted the chemokine receptor nomencla-
ture committee to register it. It was initially
designated as CCR9. However, the Steiner
group also requested a systematic nomen-
clature for their D6 clone around the same
time and was provided with CCR10 as
a designation. Therefore, for some time,
this receptor was variously known as D6,
CCR9, and CCR10! To confuse things
even further the GenBank accepted name
was “ccbp2” standing for chemokine bind-
ing protein-2. Eventually, both the CCR9
and CCR10 nomenclatures were assigned
to other receptors and D6 became the
accepted name for this molecule. How-
ever, most recently, we have developed a
systematic nomenclature system for the
entire atypical chemokine receptor fam-
ily to which D6 belongs and refer to these
as ACKRs. Within this IUPHAR approved
nomenclature system D6 is now known as
ACKR2, which is now its settled nomencla-
ture (14).
IN SUMMARY
Starting from an unusual standpoint, and
with essential input and insights from our
Milan colleagues, we have cloned and char-
acterized D6/ACKR2 as a scavenger of
inflammatory CC-chemokines and have
demonstrated its importance for the res-
olution of inflammatory response in a
variety of contexts. D6/ACKR2 provides a
paradigm for the function of other mem-
bers of the atypical chemokine receptor
family and similarities with the function of
ACKR3 and ACKR4 have already become
apparent (15). We believe that this mole-
cule has both diagnostic and therapeutic
value although this potential has yet to be
realized.
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